For research use only. Not for therapeutic Use.
Lufotrelvir（Cat No.:I031110）is an investigational antiviral compound that acts as a potent inhibitor of the SARS-CoV-2 main protease (Mpro). This protease is crucial for the virus’s replication, making Lufotrelvir an important candidate in COVID-19 treatment. By inhibiting Mpro, it prevents the processing of viral polyproteins, thereby halting viral replication. Early clinical trials suggest that Lufotrelvir has a favorable pharmacokinetic profile and strong antiviral activity, with the potential to significantly reduce viral load and improve clinical outcomes in COVID-19 patients. Its development offers hope for more effective treatments against the disease.
| Catalog Number | I031110 |
| CAS Number | 2468015-78-1 |
| Synonyms | Lufotrelvir; Lufotrelvirum; PF-07304814; PF07304814; PF 07304814; |
| Molecular Formula | C24H33N4O9P |
| Purity | 98% |
| Target | SARS-CoV |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | [(3S)-3-[[(2S)-2-[(4-methoxy-1H-indole-2-carbonyl)amino]-4-methylpentanoyl]amino]-2-oxo-4-[(3S)-2-oxopyrrolidin-3-yl]butyl] dihydrogen phosphate |
| InChI | InChI=1S/C24H33N4O9P/c1-13(2)9-18(28-24(32)19-11-15-16(26-19)5-4-6-21(15)36-3)23(31)27-17(10-14-7-8-25-22(14)30)20(29)12-37-38(33,34)35/h4-6,11,13-14,17-18,26H,7-10,12H2,1-3H3,(H,25,30)(H,27,31)(H,28,32)(H2,33,34,35)/t14-,17-,18-/m0/s1 |
| InChIKey | FQKALOFOWPDTED-WBAXXEDZSA-N |
| SMILES | CC(C)C[C@@H](C(=O)N[C@@H](C[C@@H]1CCNC1=O)C(=O)COP(=O)(O)O)NC(=O)C2=CC3=C(N2)C=CC=C3OC |
| Reference | 1: Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H, Hammond J, Hoffman R, Kadar EP, Kania R, Kimoto E, Kirkpatrick MG, Lanyon L, Lendy EK, Lillis JR, Luthra SA, Ma C, Noell S, Obach RS, O’Brien MN, O’Connor R, Ogilvie K, Owen D, Pettersson M, Reese MR, Rogers T, Rossulek MI, Sathish JG, Steppan C, Ticehurst M, Updyke LW, Zhu Y, Wang J, Chatterjee AK, Mesecar AD, Anderson AS, Allerton C. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19. bioRxiv [Preprint]. 2020 Sep 13:2020.09.12.293498. doi: 10.1101/2020.09.12.293498. PMID: 32935104; PMCID: PMC7491518. |
